Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma

Recruiting Observational Study
Neovascular Glaucoma Type 2 Diabetes
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
98 (estimated)
Sponsor
Qilu Hospital of Shandong University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this observational study is to quantify iris blood flow via non-invasive eye scanning for evaluating ocular lesions in adults aged 18 years and older, including healthy volunteers, patients with type 2 diabetes mellitus (T2DM) without fundus lesions, T2DM patients with diabetic retinopathy (DR), and T2DM patients complicated with both DR and neovascular glaucoma (NVG). The main questio…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Aged ≥ 18 years of age, regardless of gender, with or without type 2 diabetes mellitus and its associated ocular complications; clear consciousness, capable of cooperating with iris OCTA examination (able to stabilize the head to guarantee successful acquisition and interpreta…
Contacts

Yuting Zhang, Doctor of Medicine

+86 185-6008-8152

zhangyt_7085@163.com

CONTACT

Hui Guo, Doctor of Medicine

+86 185-6008-7106

guohui@sdu.edu.cn

CONTACT